Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511675 | 0.96 | MEN1 (0.73) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL7381830 | 0.96 | MEN1 (0.73) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL17539928 | 0.91 | MEN1 (0.66) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL15458662 | 0.91 | MEN1 (0.66) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL21029434 | 0.90 | KMT2A (0.64) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL782567 | 0.89 | MEN1 (1.00) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL10051515 | 0.89 | MEN1 (0.60) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL18464293 | 0.88 | MEN1 (0.62) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL24212278 | 0.84 | MEN1 (0.91) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL10051514 | 0.84 | MEN1 (0.91) | MEN1KMT2AALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264028-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| EP-4600325-B1 | ORGANIC LIGHT-EMITTING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SOLUS ADVANCED MATERIALS CO LTD (KR) | 2026-04-29 | — | — | EP | disclosed |
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-23 | — | — | US | disclosed |
| EP-3825310-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2025-11-12 | — | — | EP | disclosed |
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4600325-A1 | ORGANIC LIGHT-EMITTING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | Solus Advanced Materials Co., Ltd. (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-12384766-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-08-12 | — | — | US | disclosed |
| WO-2025135308-A1 | ORGANIC LIGHT-EMITTING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 솔루스첨단소재 주식회사 | 2025-06-26 | — | — | WO | disclosed |
| US-20250171422-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-05-29 | — | — | US | disclosed |
| WO-2002057259-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002050065-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-06-27 | — | — | WO | disclosed |
| US-6372751-B1 | DRUGS WITH BENZENE AND PYRIMIDINE RINGS | BERLEX LABORATORIES, INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1135131-A4 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LAB (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135131-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6127376-A | A BLOOD FACTOR XA ENZYME INHIBITOR TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000033844-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LATORATORIES, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| US-4016013-A | OR CARBONITRIDESDECOMPOSITION OF TRIAZINE OR PYRIMIDINE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | TNK2, CDC42, CDC42BPA | MEN1 4182/4885KMT2A 4294/4885ALDH1A1 3624/4885 |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | MEN1 4470/4885KMT2A 4623/4885ALDH1A1 3580/4885 |
| US-20250171422-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNE2, CRY2 | MEN1 880/4885KMT2A 1403/4885ALDH1A1 307/4885 |
| US-12384766-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CCNE2, CRY2 | MEN1 880/4885KMT2A 1403/4885ALDH1A1 307/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | MEN1 4519/4885KMT2A 3885/4885ALDH1A1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.